Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide Resistance

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00187551
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : February 10, 2011
Universitywide AIDS Research Program
Information provided by:
University of California, San Francisco

September 13, 2005
September 16, 2005
February 10, 2011
May 2000
November 2005   (Final data collection date for primary outcome measure)
CD4 [ Time Frame: week 24 ]
CD4, viral load, resistance assays at week 4, 12, 24, 48 after enfuvirtide interruption
Complete list of historical versions of study NCT00187551 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide Resistance
Partial Treatment Interruptions in HIV-1 Patients With Multi-Drug Resistant Virus
The goal of this study is to examine whether enfuvirtide (T20, Fuzeon) has continued anti-HIV activity in patients experiencing an incomplete virologic response to an enfuvirtide-based regimen.

Some patients do not achieve an undetectable HIV viral load with an enfuvirtide (T20, Fuzeon) based antiretroviral regimen. As a consequence, enfuvirtide resistant virus can emerge. It is not yet known if enfuvirtide has continued virologic or immunologic benefit after the drug-resistant variant emerges. Interrupting enfuvirtide may reduce the accumulation of enfuvirtide mutations and may allow for a potent response of enfuvirtide with future regimens.

Subjects must have evidence of viral replication (HIV RNA > 1,000 copies/ml on two consecutive measurements) while on a stable antiretroviral regimen containing enfuvirtide. Patients will then interrupt enfuvirtide while continuing all other antiretroviral agents. Subjects will be seen weekly for four weeks, every two weeks for an additional 8 weeks, and then every four weeks through week 48.

Plasma HIV RNA levels and CD4+/CD8+ T cell counts will be measured in real time at each visit, and provided to the referring primary care physician. Subjects will be allowed to resume enfuvirtide at any time during the course of this study. Subjects will be encouraged to resume enfuvirtide (with or without modifying the background regimen) if plasma HIV RNA levels increase by > 0.5 log on two consecutive occasions. Subjects are seen every four weeks for 24 weeks after enfuvirtide is resumed.

Plasma will be collected at those visits for HIV RNA and stored for retrospective genotype/phenotype evaluation.

Phase 4
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
HIV Infections
  • Other: Interruption of enfuvirtide
    treatment interruption
  • Other: enfuvirtide interrupton
    enfuvitide will be interrupted in patients harboring resistant virus
Experimental: interruption of enfuvirtide
enfuvirtide interruption
  • Other: Interruption of enfuvirtide
  • Other: enfuvirtide interrupton
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
November 2005
November 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Currently receiving continuous enfuvirtide-based antiretroviral therapy.
  • Documentation of recent plasma HIV RNA level greater than the lower limit of detection (measured within the preceding 4 weeks)
  • Screening plasma HIV-1 RNA level > 1000 copies/mL.
  • Negative serum pregnancy test (for women of childbearing potential) documented within the 14-day period prior to study entry.
  • Subjects must be able to give written informed consent and agree to abide by the requirements of the study.

Exclusion Criteria:

  • Unstable HIV disease status such that interrupting any antiretroviral therapy poses significant short-term risk for disease progression (as determined by study investigators and referring primary care provider).
  • Female subjects who are pregnant, breastfeeding, or who plan to become pregnant during the study.
  • Active hepatitis C infection requiring treatment with an interferon-based regimen.
  • Evidence of active, untreated opportunistic infections or unexplained temperature which is > 38.5°C for seven consecutive days, within 30 days prior to the first screening visit.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Steven Deeks, UCSF
University of California, San Francisco
Universitywide AIDS Research Program
Principal Investigator: Steven G Deeks, M.D. University of California, San Francisco
University of California, San Francisco
June 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP